Add BrightSurf on Google Email

Genetic variation enhances cancer drug sensitivity

A recent study from Uppsala University found that genetic variation in cancer cells can enhance the effects of an already approved cancer drug, talazoparib, against liver cancer cells lacking a functional CYP2D6 enzyme. This suggests a potential for more individually tailored and effective cancer therapies.

SourceUppsala University·JournalEBioMedicine·TypeExperimental study·DateNov 14, 2024

Scientists use microcellular drones to deliver lung cancer-killing drugs

Researchers successfully delivered anti-cancer ASO molecules to lung tumor sites using human red blood cells, demonstrating potent anti-cancer effects against NSCLC. The approach utilizes EGFR-targeting moieties to home in on cancerous cells, offering a potentially powerful treatment modality for personalized cancer medicine.

New antibody could be promising cancer treatment

Researchers at Uppsala University have developed a unique antibody that targets and delivers a drug package while activating the immune system. This '3-in-1 design' method has shown promise in treating several types of cancer by amplifying T cell effect on cancer tumors.

SourceUppsala University·JournalNature Communications·TypeExperimental study·DateNov 11, 2024

A 36-gene predictive score of anti-cancer drug resistance anticipates cancer therapy outcomes

Researchers developed a 36-gene predictive score that surpasses conventional methods in predicting tamoxifen treatment resistance. The polygenic score UAB36 has potential as a tool for personalized medicine, helping identify patients at higher risk of poor survival and suggesting alternative treatment strategies.

SourceUniversity of Alabama at Birmingham·Journalnpj Precision Oncology·TypeMeta-analysis·DateNov 7, 2024

An old drug with new tricks

A new study by MUSC researchers reveals how cancer cells develop resistance to hydroxychloroquine, an anti-malarial drug repurposed for cancer therapy. The findings suggest that targeting specific metabolic and export pathways can prevent resistance, opening the door for novel combination therapies.

SourceMedical University of South Carolina·JournalCell Cycle·TypeExperimental study·DateNov 4, 2024

Novel immunotherapy combo shows promise in melanoma

A phase 2 clinical trial found that the combination of vidutolimod and nivolumab led to tumor control in 55% of patients, with higher levels of immune-related proteins detected in responders. The study also uncovered unique signatures of TLR9 activation and a link between gut microbiome and response to therapy.

SourceUniversity of Pittsburgh·JournalCancer Cell·TypeRandomized controlled/clinical trial·DateNov 1, 2024

New anti-cancer agent works without oxygen

A new anti-cancer agent has been developed that targets glutathione in cancer cells, switching it off and causing tumor shrinkage. The catalyst-based therapy accumulates specifically in tumor tissue, showing promising results in animal studies and potential for further human trials.

SourceRuhr-University Bochum·JournalNature Communications·TypeExperimental study·DateOct 31, 2024

Patients with advanced bladder cancer with alterations in the FGFR3 gene respond well to investigational drug, TYRA-300

TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.

SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateOct 24, 2024

Treatments used for HER2-positive breast cancers could help patients with rare gastrointestinal cancer

A clinical trial suggests that tucatinib and trastuzumab may benefit patients with rare bile duct cancer who also have HER2-mutated breast cancer. The treatment combination showed a 46.7% objective response rate in patients with bile duct cancer, compared to 22.2% in the broader patient group.

A mushroom for colorectal cancer therapy

Researchers discovered a previously unknown class of compounds in the fungus Bipolaris victoriae S27 that effectively kill colorectal cancer cells. The most effective compound, bipoterpride No. 2, targets the DCTPP1 enzyme and shows promise as a potential new treatment option.

SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateOct 17, 2024

Highly-stabilized and selective inhibitor for cancer-causing enzyme revealed

Researchers at the Hebrew University of Jerusalem have developed a highly selective inhibitor for Matrix Metallopeptidase 7 (MMP7), an enzyme crucial for cancer spread and progression. The novel peptide D'20 demonstrates remarkable stability and selectivity, targeting MMP7 while leaving similar enzymes unaffected.

SourceThe Hebrew University of Jerusalem·JournalAngewandte Chemie·TypeExperimental study·DateOct 15, 2024

CNIO researchers propose a new treatment for brain metastasis based on immunotherapy

Researchers at CNIO propose a new treatment for brain metastasis by targeting pro-tumour astrocytes with immunotherapy. They identified TIMP1 as a biomarker to predict when immunotherapy is effective, and a clinical trial is underway to test the therapeutic efficacy of silibinin inhibition.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalCancer Discovery·TypeExperimental study·DateOct 2, 2024

Antidepressant shows promise for treating brain tumors

Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.

SourceETH Zurich·JournalNature Medicine·TypeComputational simulation/modeling·DateSep 20, 2024

New law regulating out-of-pocket drug spending saves cancer patients more than $7,000 a year, study finds

A new study by Michigan Medicine found that the Inflation Reduction Act's limit on Medicare Part D spending leads to significant savings for cancer patients prescribed oral chemotherapy. The average annual cost for these medications decreased from $11,284 in 2023 to $3,927 in 2024, resulting in median cost savings of $7,260.

SourceMichigan Medicine - University of Michigan·JournalJAMA Network Open·TypeData/statistical analysis·DateSep 10, 2024

When is the best time of day for cancer treatment?

Researchers have identified certain times of the day when cancer cells are most responsive to medication-based treatments, suggesting personalized treatment plans could improve efficacy and reduce side effects. The study used a method called high-throughput deep phenotyping to analyze the circadian rhythms of breast cancer cell lines.

SourceCharité - Universitätsmedizin Berlin·JournalNature Communications·TypeImaging analysis·DateAug 23, 2024

Precision therapy for metastatic prostate cancer improves survival

A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.

SourceKarolinska Institutet·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateAug 20, 2024

Ontario Institute for Cancer Research announces awards for eight research teams developing innovative ways to diagnose and treat cancer

The Ontario Institute for Cancer Research is providing nearly $6 million to eight research teams across Ontario, supporting studies that aim to diagnose and treat cancers more effectively. The Clinical Translational Pathway program will advance new discoveries and bring them to the healthcare system.

Drug shows promise for treating brain tumors resulting from breast cancer, UT Health San Antonio trial reports

A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.

SourceUniversity of Texas Health Science Center at San Antonio·JournalNature Communications·TypeRandomized controlled/clinical trial·DateAug 8, 2024

Combination of drugs produces promising results in combating cancer and will be clinically trialed in Europe

Researchers developed a new approach to combat cancer by hyperactivating tumor cells, making them stressed and vulnerable to specific drugs. The combination strategy showed promising results in colorectal and pancreatic adenocarcinoma models, paving the way for potential treatment options.

Long-term results from Testicular Cancer treatment are positive, study shows

A recent study published in the Journal of Clinical Oncology found that combining different chemotherapy drugs improves testicular cancer's treatability and often curability, even after first-line treatment fails. The study showed a nearly 80% response rate and no significant drop-off in survival over 10 years.

SourceUniversity College Cork·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateJul 19, 2024

Novel drug application shows improved survival for patients with relapsed and refractory acute myeloid leukemia

A novel strategy using venetoclax and azacitidine demonstrates significant anti-cancer effect with mild toxicity for relapsed/refractory AML patients. The treatment showed markedly better survival rates after one year compared to a control group, with improved 'graft-versus-leukemia effects' via alterations of immune cells.

SourceOsaka Metropolitan University·JournalBlood Cancer Journal·TypeObservational study·DateJul 18, 2024

New technique could help treat aggressive brain tumors

Researchers have developed a new technique called burst sine wave electroporation (B-SWE) that can disrupt the blood-brain barrier around brain tumors without causing significant damage to healthy tissue. This method shows promise for treating aggressive brain cancers like glioblastoma, which currently have limited treatment options.

SourceVirginia Tech·JournalAPL Bioengineering·DateJul 17, 2024